Reading RCUS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RCUS free→Reading RCUS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RCUS free→NYSEHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and the company was unprofitable over the past year, so its earnings quality can't be assessed. Management's recent track record has been steady, but risk is elevated, and the sector backdrop is a headwind. Peer multiples imply a price about 15% above where it trades (it looks cheap on this basis); the read is fair, but weakening, as it is priced roughly in line with peers, but recent financials or earnings quality are weakening. Key factors to watch include guidance changes and sector trends, particularly how bellwethers perform. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $24.18. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $24 RCUS trades at 10× p/s, in line with its 9× p/s peer median. Our $28 fair value reflects that, medium confidence. Analysts: $22–$47. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 13% below a flat-multiple fair value, well above our forecast of about -60%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 1.32x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.78 → $-0.81 (-5.1% / 30d). 1 raised, 0 cut, 7 covering analysts.
0 upgrades, 0 downgrades / 30d. 77% of analysts rate Buy.
1 PT revisions / 30d. Avg target 47.2% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$252.
How much price usually moves either way.
On a bad day, this stock has moved -$634.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,778.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation label changed from 'inexpensive' to 'fair'.
The valuation dimension changed, as the valuation label moved from "inexpensive" to "fair." Risk remained elevated. The sector backdrop was noted as a headwind. Recent financial performance was described as weak.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Higher revenue shows progress after a big drop.
Confirms:Q2 revenue shows growth compared to $17M in Q1.
Disproves:Q2 revenue continues to decline or stays below $17M.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for RCUS yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
of this Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
$22.00 – $47.00 (median $35.00) · 3 analysts · as of 2026-05-18
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Roughly priced in line with peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
RCUS Arcus Biosciences, Inc. | Below typical Show detailsSector percentile: 24 of 100 | fair | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
3 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue collaboration with Gilead Sciences, despite the discontinuation of the STAR-121 study.
Emphasize revenue growth despite recent declines in quarterly revenue.
Continue efforts to manage and reduce operating losses.
Why it matters: Revenue growth is a priority. It shows if the company is improving its financial health.
Confirms:Revenue growth reported above 10% year over year in the next earnings report.
Disproves:Revenue growth reported below 5% year over year.
Why it matters: Increasing losses would show challenges in managing costs and could raise concerns.
Confirms:Operating losses are over -$134M reported in Q1.
Disproves:Operating losses improve or stay below -$134M.
Why it matters: Initial data will show how well casdatifan works for treating kidney cancer.
Confirms one read:Initial data from ARC-20 groups looks at casdatifan in early treatment settings.
Confirms the other:No initial data is shown from ARC-20 groups in early-line settings.
Why it matters: The outcome of this study impacts the partnership with Gilead and future treatments.
Confirms one read:Announcement of a new study or trial that replaces the discontinued STAR-121.
Confirms the other:No new studies are announced. Focus remains on the stopped STAR-121.
Why it matters: Progress in this partnership is key for growth. It impacts future revenue potential.
Confirms:Gilead made a public announcement. It is about new projects or milestones.
Disproves:No updates or delays in work with Gilead.
Why it matters: Managing losses is key for financial health. It affects how investors feel.
Confirms:Operating losses decrease by more than 10% in the next financial report.
Disproves:Operating losses go up or stay the same.
Other Events. STAR-121 Update . On April 20, 2026, Arcus Biosciences, Inc. (the “ Company ”) announced the discontinuation of the Phase 3 STAR-121 study, which is being conducted in collaboration with Gilead Sciences, Inc. (“ Gilead ”), due to futility. STAR-121 evaluated the anti-TIGIT antibody domvanalimab plus anti-PD-1 antibody zimberelimab and chemotherapy versus pembrolizumab plus chemotherapy as a first-line treatment for metastatic non-small cell lung cancer. The decision is based on…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 17, 2026, Jennifer Jarrett notified Arcus Biosciences, Inc. (the “Company”) of her decision to resign from her position as Chief Operating Officer, effective as of March 30, 2026. Ms. Jarrett’s resignation is not the result of any disagreement with the Company regarding its operations, policies or practices. The Company and Ms. Jarrett ent…
of this Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.
Other Events. ARC-20 Updates On October 6, 2025, Arcus Biosciences, Inc. (the “Company”) presented updated data from the monotherapy cohorts of ARC-20, a Phase 1/1b study evaluating different doses and combinations with casdatifan, and shared new research programs in immunology and inflammation. A copy of the presentation has been posted to the Investors & Media section of the Company’s website. The presentation included updated data from four monotherapy cohorts evaluating casdatifan in pati…